Targeting glycosylation as a therapeutic approach

Nature Reviews Drug Discovery

Volumn 1, Issue 1, 2002, Pages 65-75

  Dwek, Raymond A ^a   Butters, Terry D ^a   Platt, Frances M ^a   Zitzmann, Nicole ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; AMINOGLYCOSIDE DERIVATIVE; ANTIVIRUS AGENT; CARBOHYDRATE; CARBOHYDRATE DERIVATIVE; CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE; GANGLIOSIDE GM2; GLUCOSE; GLYCAN; GLYCOPROTEIN; GLYCOSIDASE; GLYCOSPHINGOLIPID; GLYCOSYLTRANSFERASE; LIPID; MANNOSIDASE INHIBITOR; MIGLITOL; MIGLUSTAT; N BUTYLDEOXYGALACTONOJIRIMYCIN; N NONYLDEOXYGALACTONOJIRIMYCIN; N NONYLDEOXYNOJIRIMYCIN; OGT 923; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CELL FUNCTION; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; GAUCHER DISEASE; GLYCOPROTEIN SYNTHESIS; GLYCOSYLATION; GOLGI COMPLEX; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPIDOSIS; LYSOSOME; LYSOSOME STORAGE DISEASE; MODULATION; NIEMANN PICK DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; SANDHOFF DISEASE; TAY SACHS DISEASE; VIREMIA; VIRION; VIRUS INFECTION; ANIMAL; BIOSYNTHESIS; BOVINE DIARRHEA VIRUS; DISEASE MODEL; DRUG EFFECT; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM; MOUSE;

ANIMALS; ANTIVIRAL AGENTS; DIARRHEA VIRUSES, BOVINE VIRAL; DISEASE MODELS, ANIMAL; GAUCHER DISEASE; GLYCOPROTEINS; GLYCOSPHINGOLIPIDS; GLYCOSYLATION; HEPATITIS B VIRUS; HIV; HUMANS; MICE; PROTEIN FOLDING;

EID: 0036052503     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd708     Document Type: Review

References (87)

1. Zapun, A. et al. Conformation-independent binding of monoglucosylated ribonuclease B to calnexin. Cell 88, 29-38 (1997).
2. Rudd, P. M. et al. Roles for glycosylation of cell surface receptors involved in cellular immune recognition. J. Mol. Biol. 293, 351-366 (1999).
3. Weis, W. I., Taylor, M. E. & Drickamer, K. The C-type lectin superfamily in the immune system. Immunol. Rev. 163, 19-34 (1998).
4. Marquardt, T. & Freeze, H. Congenital disorders of glycosydation: glycosylation defects in man and biological models for their study. Biol. Chem. 382, 161-177 (2001).
5. Dwek, R. A. Glycobiology: 'towards understanding the function of sugars'. Biochem. Soc. Trans. 23, 1-25
6. Dennis, J. W., Granovsky, M. & Warren, C. E. Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta 1473, 21-34 (1999).
7. Parekh, R. B. et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316, 452-457(1985).
8. Yamashita, T. et al. A vital role for glycosphingolipid synthesis during development and differentiation. Proc. Natl Acad. Sci. USA 96, 9142-9147 (1999).
9. Walkley S. U. Cellular pathology of lysosomal storage disorders. Brain Pathol. 8, 175-193 (1998).
10. Winchester, B. & Fleet, G. W. Amino-sugar glycosidase inhibitors: versatile tools for glycobiologists. Glycobiology 2, 199-210 (1992).
11. Butters, T., Dwek, R. & Platt, F. Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders. Chem. Rev. 100, 4683-4696 (2000).
12. Butters, T. D. et al. Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycospingolipid biosynthesis. Tetrahedron Asymmetry 11, 113-124 (2000).
13. Jacob, G. S. Glycosylation inhibitors in biology and medicine. Curr. Opin. Struct. Biol. 5, 605-611 (1995).
14. Mitrakou, A. et al. Long-term effectiveness of a new α-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus. Diabet. Med. 15, 657-660 (1998).
15. Goss, P. E., Reid, C. L., Bailey, D. & Dennis, J. W. Phase 1B clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies. Clin. Cancer Res. 3, 1077-1086 (1997).
16. Bergeron, J. J., Brenner, M. B., Thomas, D. Y. & Williams, D. B. Calnexin: a membrane-bound chaperone of the endoplasmic reticulum. Trends Biochem. Sci. 19, 124-128 (1994).
17. Peterson, J. R., Ora, A., Van, P. N. & Helenius, A. Transient, lectin-like association of calreticulin with folding intermediates of cellular and viral glycoproteins. Mol. Biol. Cell 6, 1173-1184 (1995).
18. Mehta, A., Zitzmann, N., Rudd, P. M., Block, T. M. & DweK, R. A. α-glucosidase inhibitors as potential broad based anti-viral agents. FEBS Lett. 430, 17-22 (1998).
19. McGinnes, L. W. & Morrison, T. G. Role of carbohydrate processing and calnexin binding in the folding and activity of the HN protein of Newcastle disease virus. Virus Res. 53, 175-185 (1998).
20. Mirazimi, A., Nilsson, M. & Svensson, L. The molecular chaperone calnexin interacts with the NSP4 enterotoxin of rotavirus in vivo and in vitro. J. Virol. 72, 8705-8709 (1998).
21. Werr, M. & Prange, R. Role for calnexin and N-linked glycosylation in the assembly and secretion of hepatitis B virus middle envelope protein particles. J. Virol. 72, 778-782 (1998).
22. Branza-Nichita, N., Durantel, D., Carrouee-Durantel, S., Dwek, R. A. & Zitzmann, N. Antiviral effect of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers. J. Virol. 75, 3527-3536 (2001).
23. Choukhi, A., Ung, S., Wychowski, C. & Dubuisson, J. Involvement of endoplasmic reticulum chaperones in the folding of hepatitis C virus glycoproteins. J. Virol. 72, 3851-3858 (1998).
24. Repp, R. et al. The effects of processing inhibitors of N-linked oligosaccharides on the intracellular migration of glycoprotein E2 of mouse hepatitis virus and the maturation of coronavirus particles. J. Biol. Chem. 260, 15873-15879(1985).
25. Schlesinger, S., Koyama, A. H., Malfer, C., Gee, S. L. & Schlesinger, M. J. The effects of inhibitors of glucosidase I on the formation of Sindbis virus. Virus Res. 2, 139-149 (1985).
26. Pinter, A., Honnen, W. J. & Li, J. S. Studies with inhibitors of oligosaccharide processing indicate a functional role for complex sugars in the transport and proteolysis of Friend mink call focus-inducing murine leukemia virus envelope proteins. Virology 136, 196-210 (1984).
27. Poss, M. L., Mullins, J. I. & Hoover, E. A. Posttranslational modifications distinguish the envelope glycoprotain of the immunodeficiency disease-inducing feline leukemia virus retrovirus. J. Virol. 63, 189-195 (1989).
28. Ratner, L., Vander Heyden, N. & Dedera, D. Inhibition of HIV and SIV infectivity by blockade of α-glucosidase activity. Virology 181, 180-192 (1991).
29. Lu, X., Mehta, A., Dwek, R., Butters, T. & Block, T. Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion, Virology 213, 660-665 (1995).
30. Durantel, D. et al. Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J. Virol. 75, 8987-8998 (2001).
31. Freed, E. O. & Martin, M. A. in Fields Virology 4th edn Vol. 2 (eds Knipe, D. M. et al.) 1971-2041 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
32. Fischer, P. B. et al. The α-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J. Virol. 69, 5791-5797 (1995).
33. Elbein, A. D. Glycosidase inhibitors as antiviral and/or antitumor agents. Semin. Cell Biol. 2, 309-317 (1991).
34. Fischer, P. B., Karlsson, G. B., Dwek, R. A. & Platt, F. M. N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp 120 shedding and gp41 exposure. J. Virol. 70, 7153-7160 (1996).
35. Fischer, P. B., Karlsson, G. B., Butters, T. D., Dwek, R. A. & Platt, F. M. N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1N2 region of gp 120. J. Virol. 70, 7143-7152 (1996).
36. Platt, F. M. & Butters, T. D. Substrate deprivation: A new therapeutic approach for the glycosphingolipid lysosomal storage diseases. Exp. Rev. Mol. Med. (2000). [http://www-ermm.cbcu.cam.ac.uk/00001484h.htm].
37. 3. J. Acquir. Immune Defic. Syndr, 7, 139-147 (1994).
38. Hollinger, F. B. & Liang, T. J. in Fields Virology 4th edn Vol. 2 eds Knipe, D. M. et al.) 2971-3036 (Lippincott, Williams and Willkins, Philadelphia, 2001).
39. Block, T. M. et al. Secretion of human hepatitis B virus is inhibited by the imino, sugar N-butyldeoxynojirimycin. Proc. Natl Acad. Sci. USA 91, 2235-2239 (1994).
40. Mehta, A., Lu, X., Block, T. M., Blumberg, B. S. & Dwek, R. A. Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proc. Natl Acad. Sci. USA 94, 1822-1827 (1997).
41. Moore, S. E. & Spiro, R. G. Demonstration that Golgi endo-α-D-mannosidase provides a glucosidase-independent pathway for the formation of complex N-linked oligosacchandes of glycoproteins. J. Biol. Chem. 265, 13104-13112 (1990).
42. Block, T. M. at al. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an Inhibitor of protein folding and trafficking. Nature Med. 4, 610-614 (1998).
43. Lindenbach, B. D. & Rice, C. M. Flaviviridae: in Fields Virology 4th edn Vol. 1 (eds Knipe, D. M. et al.) 991-1041 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
44. Deleersnyder, V. et al. Formation of native hepatitis C virus glycoprotein complexes. J. Virol 71, 697-704 (1997).
45. Zitzmann, N. et al. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivinus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc. Natl Acad. Sci. USA 96, 11878-11882 (1999).
46. Andersson, U., Butters, T. D., Dwek, R. A. & Platt, F. M. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem. Pharmacol. 59, 821-829 (2000).
47. Mehta, A. at al. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology 33, 1488-1495 (2001).
48. Meikle, P. J., Hopwood, J. J., Clague, A. E. & Carey, W. F. Prevalence of lysosomal storage disorders. J. Am. Med. Assoc. 281, 249-254 (1999).
49. Beutler, E. & Grabowski, G. in Gaucher Disease (eds Scriver, C. R., Beadet, A. L., Valle, D. & Sly, W. S.) 3635-3668 (McGraw Hill, New York, 2001).
50. Vunnam, R. R. & Radin, N. S. Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem. Phys. Lipids 26, 265-278 (1980).
51. Radin, N. S. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj. J. 13, 153-157 (1996).
52. Platt, F. M. & Butters, T. D. Inhibitors of glycosphingolipid biosynthesis. Trends Glycosci. Glycotechnol. 7, 495-511 (1995).
53. Platt, F. M. & Butters, T. D. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases. Biochem. Pharmacol. 56, 421-430 (1998).
54. Platt, F. M., Neises, G. R., Dwek, R. A. & Butters, T. D. N-butyldeoxynojirimycin is a novel inhibitor of glycoliplid biosynthesis. J. Biol. Chem. 269, 8362-8365 (1994).
55. Platt, F. M., Karlsson, G. B. & Jacob, G. S. Modulation of cell-surface transferrin receptor by the imino sugar N-butyideoxynojirimycin. Eur. J. Biochem. 208,187-193 (1992).
56. Platt, F. M., Neises, G. R., Karlsson, G. B., Dwek, R. A. & Butters, T. D. N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosacchande processing. J. Biol. Chem. 269, 27108-27114 (1994).
57. Suzuki, K., Proia, R. L. & Suzuki, K. Mouse models of human lysosomal diseases. Brain Pathol. 8, 195-215 (1998).
58. Platt, F. M., Reinkensmeier, G., Dwek, R. A. & Butters, T. D. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J. Biol. Chem. 272, 19365-19372 (1997).
59. Yamanaka, S. et al. Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Proc. Natl Acad. Sci. USA 91, 9975-9979 (1994).
60. Taniike, M. et al. Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease. Acta NeuroPathol. (Berl.) 89, 296-304 (1995).
61. Sango, K. et al. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nature Genet. 11, 170-176 (1995).
62. Platt, F. M. et al. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276, 428-431 (1997).
63. Jeyakumar, M. et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin, Proc. Natl Acad. Sci. USA 96, 6388-6393 (1999).
64. Jeyakumar, M. et al. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood 97, 327-329 (2001).
65. Liu, Y. at al. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J. Clin. Invest. 103, 497-505 (1999).
66. Zervas, M., Somers, K. L., Thrall, M. A. & Walkley, S. U. Critical role for glycosphingolipids in Niemann-Pick C disease type C. Curr. Biol. 11, 1283-1287 (2001).
67. Liu, Y. et al. Alleviation of neuronal ganglioside storage does not improve the clinical course of the Niemann-Pick-C disease mouse. Hum. Mol. Genet. 9, 1087-1092 (2000).
68. Cox, T. et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OCT 918) to decrease substrate biosynthess. Lancet 355, 1481-1485 (2000).
69. Priestman, D. A., Platt, F. M., Dwek, R. A. & Butters, T. D. Imino sugar therapy for type 1 Gaucher disease. Glycobiology 10, 4-5 (2000).
70. Lachmann, R. H. & Platt, F. M. Substrate reduction therapy for glycosphingolipid storage disorders. Exp. Opin. Invest, Drugs 10, 455-466 (2001).
71. Taylor, D. L. et al. 6-0-butanoylcastanospermine (MDL 28,574) inhibits glycoprotein processing and the growth of HIV.AIDS 5, 693-698 (1991).
72. Sunkara, P. S., Bowlin, T. L., Liu, P. S. & Sjoerdsma, A. Antiretroviral activity of castanospermine and deoxynojirimycin, specific inhibitors of glycoprotein processing, Biochem. Biophys. Res. Commun. 148, 206-210 (1987).
73. Bridges, C. G. et al. The effect of oral treatment with 6-O-butanoyl castanospermine (MDL 28,574) in the murine zosteriform model of HSV-1 infection. Glycobiology 5, 249-253 (1995)
74. Ahmed, S. P. et al. Antiviral activity and metabolism of the castanospermine derivative MDL 28,574, in cells infected with herpes simplex virus type 2. Biochem. Biophys. Res. Commun. 208, 267-273 (1995).
75. Gretch, D. R., Gehrz, R. C. & Stinski, M. F. Characterization of a human cytomegalovirus glycoprotein complex (gcl). J. Gen. Virol. 69, 1205-1215 (1988).
76. Taylor, D. L. et al. Loss of cytomegalovirus infectivity after treatment with castanospermine or related plant alkaloids correlates with aberrant glycoprotein synthesis. Antiviral Res. 10, 11-26 (1988).
77. Datema, R., Romero, P. A., Rott, R. & Schwarz, R. T. On the role of oligosaccharide trimming in the maturation of Sindbis and influenza virus. Arch. Virol. 81, 25-39 (1984).
78. McDowell, W., Romero, P. A., Datema, R. & Schwarz, R. T. Glucose trimming and mannose trimming affect different phases of the maturation of Sindbis virus in infected BHK cells. Virology 161, 37-44 (1987).
79. Kaluza, G., Repges, S. & McDowell, W. The significance of carbohydrate trimming for the antigenicity of the Semliki Forest virus glycoprotein E2. Virology 176, 369-378 (1990).
80. Repges-Illguth, S. & Kaluza, G. Differences in antigenicity of E2 in Semliki Forest virus particles and in infected cells. Arch. Virol. 135, 433-435 (1994).
81. Schlesinger, S., Malfer, C. & Schlesinger, M. J. The formation of vesicular stomatitis virus (San Juan strain) becomes temperature-sensitive when glucose residues are retained on the oligosaccharides of the glycoprotein. J. Biol. Chem. 259, 7597-7601 (1984).
82. Malvoisin, E. & Wild, F. The role of N-glycosylation in cell fusion induced by a vaccinia recombinant virus expressing both measles virus glycoproteins. Virology 200, 11-20 (1994).
83. Courageot, M. P., Frankel, M. P., Dos Santos, C. D., Deubel, V. & Despres, P. α-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J. Virol. 74, 564-572 (2000).
84. Lad, V. J., Shende, V. R., Gupta, A. K., Koshy, A. A. & Roy, A. Effect of tunicamycin on expression of ectopes on Japanese encephalitis virus glycoprotein E in porcine kidney cells. Acta Virol. 44, 359-364 (2000).
85. Wright, K. E., Spiro, R. C., Burns, J. W. & Buchmeier, M. J. Post-translational processing of the glycoproteins of lymphocytic choriomeningitis virus. Virology 177, 175-183 (1990).
86. Silber, A. M., Candurra, N. A. & Damonte, E. B. The effects of oligosaccharide trimming inhibitors on glycoprotein expression and infectivity of Junin virus. FEMS Microbiol. Lett. 109, 39-43 (1993).
87. Jarvis, D. L. & Garcia, A. Jr. Biosynthesis and processing of the Autographa californica nuclear polyhedrosis virus gp64 protein. Virology 205, 300-313 (1994).